Mankind Pharma reports Q4FY26 revenue up 11.8% with adj. EBITDA margin at 27.1%; FY26 revenue ₹14,278 crore and EBITDA ₹3,629 crore amid domestic growth and subdued international performance.
AI Assistant
Mankind Pharma Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.